UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Idiopathic Pulmonary Fibrosis

The New England journal of medicine, 2018-05, Vol.378 (19), p.1811-1823

2018

Volltextzugriff (PDF)

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

JAMA : the journal of the American Medical Association, 2021-08, Vol.326 (6), p.499

2021

Volltextzugriff (PDF)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

American journal of respiratory and critical care medicine, 2016-08, Vol.194 (3), p.265-275

2016

Volltextzugriff (PDF)

Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward

The European respiratory journal, 2013-12, Vol.42 (6), p.1446-1448

Lederer, David J

2013

Volltextzugriff (PDF)

Genome-wide association analysis identifies six new loci associated with forced vital capacity

Nature genetics, 2014-07, Vol.46 (7), p.669-677

2014

Volltextzugriff (PDF)

S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study

Thorax, 2022-11, Vol.77 (Suppl 1), p.A77-A78

2022

Volltextzugriff (PDF)

P38 Dupilumab Improves Quality of Life in Caregivers of Children with Uncontrolled Moderate-to-Severe Asthma: Liberty Asthma Voyage Study

Value in health, 2022-07, Vol.25 (7), p.S294-S295

2022

Volltextzugriff (PDF)

CO87 Reductions in Exacerbations and Improvements in Lung Function and Asthma Control in Children With Moderate-to-Severe Type 2 Asthma Analyzed by High- or Medium-Dose of Inhaled Corticosteroids at Baseline

Value in health, 2022-12, Vol.25 (12), p.S34-S35

2022

Volltextzugriff (PDF)

PCR69 Sustained Improvement in Asthma Control with Dupilumab Treatment in Patients with Uncontrolled, Moderate-to-Severe Type 2 Asthma: Post Hoc Analysis of Liberty Asthma Traverse Open-Label Extension Study

Value in health, 2022-07, Vol.25 (7), p.S553-S554

2022

Volltextzugriff (PDF)

P174 Effect of continued treatment with pirfenidone following a ≥10% relative decline in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF)

Thorax, 2016-12, Vol.71 (Suppl 3), p.A178-A178

2016

Volltextzugriff (PDF)

S97 Annual rate of fvc decline in various patient sub-groups with idiopathic pulmonary fibrosis treated with pirfenidone: pooled analysis from 3 pivotal studies

Thorax, 2016-12, Vol.71 (Suppl 3), p.A57-A57

2016

Volltextzugriff (PDF)

P14 Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung function

Thorax, 2015-12, Vol.70 (Suppl 3), p.A81-A81

2015

Volltextzugriff (PDF)

P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials: Abstract P13 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A80-A81

2015

Volltextzugriff (PDF)

S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)

Thorax, 2015-12, Vol.70 (Suppl 3), p.A62

2015

Volltextzugriff (PDF)

P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials

Thorax, 2015-12, Vol.70 (Suppl 3), p.A80

2015

Volltextzugriff (PDF)

S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF): Abstract S109 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A62-A63

2015

Volltextzugriff (PDF)

Immunoglobulin G Levels before and after Lung Transplantation

American journal of respiratory and critical care medicine, 2006-04, Vol.173 (8), p.917-921

2006

Volltextzugriff (PDF)

Racial and Ethnic Disparities in Survival in Lung Transplant Candidates with Idiopathic Pulmonary Fibrosis

American journal of transplantation, 2006-02, Vol.6 (2), p.398-403

2006

Volltextzugriff (PDF)

Outcomes of extended donor lung recipients after lung transplantation

Transplantation, 2005-02, Vol.79 (3), p.310-316

2005

Volltextzugriff (PDF)

ADRB2 (Adrenergic B2 Receptor Agonist Gene) Arg 16 Allele and Effect of LABA Withdrawal in Patients with Moderate to Severe Asthma

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB67-AB67

2011

Volltextzugriff (PDF)

Osteoporosis in Diffuse Parenchymal Lung Disease

Chest, 2006-01, Vol.129 (1), p.140-146

2006

Volltextzugriff (PDF)

Successful Bilateral Lung Transplantation for Pulmonary Fibrosis Associated With the Hermansky-Pudlak Syndrome

The Journal of heart and lung transplantation, 2005-10, Vol.24 (10), p.1697-1699

2005

Volltextzugriff (PDF)

Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease

Pneumologie (Stuttgart, Germany), 2016, Vol.70 (S 01)

2016

Volltextzugriff (PDF)

Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)

Pneumologie (Stuttgart, Germany), 2016, Vol.70 (S 01)

2016

Volltextzugriff (PDF)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials

Pneumologie (Stuttgart, Germany), 2016, Vol.70 (S 01)

2016

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(35)
Tagungsberichte
(5)

Sprache

Englisch
(40)
Deutsch
(4)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Idiopathic Pulmonary Fibrosis

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward

Genome-wide association analysis identifies six new loci associated with forced vital capacity

S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study

P38 Dupilumab Improves Quality of Life in Caregivers of Children with Uncontrolled Moderate-to-Severe Asthma: Liberty Asthma Voyage Study

CO87 Reductions in Exacerbations and Improvements in Lung Function and Asthma Control in Children With Moderate-to-Severe Type 2 Asthma Analyzed by High- or Medium-Dose of Inhaled Corticosteroids at Baseline

PCR69 Sustained Improvement in Asthma Control with Dupilumab Treatment in Patients with Uncontrolled, Moderate-to-Severe Type 2 Asthma: Post Hoc Analysis of Liberty Asthma Traverse Open-Label Extension Study

P174 Effect of continued treatment with pirfenidone following a ≥10% relative decline in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF)

S97 Annual rate of fvc decline in various patient sub-groups with idiopathic pulmonary fibrosis treated with pirfenidone: pooled analysis from 3 pivotal studies

P14 Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung function

P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials: Abstract P13 Table 1

S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)

P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials

S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF): Abstract S109 Table 1

Immunoglobulin G Levels before and after Lung Transplantation

Racial and Ethnic Disparities in Survival in Lung Transplant Candidates with Idiopathic Pulmonary Fibrosis

Outcomes of extended donor lung recipients after lung transplantation

ADRB2 (Adrenergic B2 Receptor Agonist Gene) Arg 16 Allele and Effect of LABA Withdrawal in Patients with Moderate to Severe Asthma

Osteoporosis in Diffuse Parenchymal Lung Disease

Successful Bilateral Lung Transplantation for Pulmonary Fibrosis Associated With the Hermansky-Pudlak Syndrome

Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease

Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials

Suchergebnisse filtern